Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD2 | Q9BYW2 | 5/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 2/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641039 | 0.93 | SETD2 (0.37) | SETD2NPY5RHTR3ATACR1AKT1 | |
| SCHEMBL13640775 | 0.93 | SETD2 (0.37) | SETD2NPY5RHTR3ATACR1AKT1 | |
| SCHEMBL13641025 | 0.93 | SETD2 (0.41) | SETD2NPY5RHTR3ATACR1AKT1 | |
| SCHEMBL13640957 | 0.89 | SETD2 (0.41) | SETD2NPY5RHTR3ATACR1AKT1 | |
| SCHEMBL13640875 | 0.89 | SETD2 (0.41) | SETD2NPY5RHTR3ATACR1AKT1 | |
| SCHEMBL13640990 | 0.88 | SETD2 (0.38) | SETD2NPY5RHTR3ATACR1AKT1 | |
| SCHEMBL13640905 | 0.87 | NOTUM (0.39) | SETD2AKT1CTSSNSD2CYP2C8 | |
| SCHEMBL13641037 | 0.84 | AXL (0.37) | SETD2CTSSNSD2CYP2C8DRD2 | |
| SCHEMBL12084274 | 0.82 | PSEN1 (0.39) | NPY5RHTR3ATACR1AKT1 | |
| SCHEMBL12084908 | 0.81 | NPY5R (0.38) | NPY5RTACR1AKT1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | SETD2 3573/4885NPY5R 663/4885HTR3A 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.